CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study

Nov 14, 2017
By Applied Clinical Trials Editors

CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers. 

Read the full release here.

native1_300x100
lorem ipsum